Is Alpelisib currently available in regular domestic hospitals or pharmacies?

Alpelisib (Alpelisib) is a targeted drug mainly used to treat PIK3CA mutated HR positive, HER2 negative advanced breast cancer. It belongs to the PI3K inhibitor drug class. In recent years, with the development of personalized treatment, this drug has gained widespread attention overseas. However, Apelvis has not yet been approved for marketing by the State Food and Drug Administration in mainland China, so it cannot be purchased directly in regular domestic hospitals or pharmacies.

Because it is not yet on the market, Apelvis has not been included in the national medical insurance directory. If domestic patients want to use this drug, they can only obtain it through overseas channels. At present, the more common methods include purchasing through overseas medical service institutions or cross-border drug purchasing platforms, among which the Indian and Laos versions are more common. Among them, the original drug produced by Novartis (Novartis) on the market in India has international certification for its efficacy and quality, and the price is about more than 3,000 yuan per box.

In addition to the original drug, Apelvis also has generic versions produced by Lao pharmaceutical companies to choose from. These generic drugs are lower in cost and relatively affordable. It is understood that the Laotian version of Apelvis sells for about more than 1,000 yuan per box, making it an important alternative for many patients with limited financial conditions. Although the ingredients of generic drugs are basically the same as those of original drugs, they still need to be purchased through formal channels to ensure the quality and safety of the drugs.

In general, although Apelvis has not yet been launched in China and patients cannot obtain it through domestic hospitals and pharmacies, they can obtain Indian original drugs or Laotian generic drugs through overseas drug purchase channels. It is recommended that patients use it rationally under the guidance of a doctor and carefully choose regular drug purchasing channels to ensure drug safety and therapeutic effect. At the same time, you can also pay close attention to the approval progress of drugs in the country, which may be included in the national drug supply system in the future.

Reference materials:https://www.drugs.com/